Is It Possible to Differentiate Chronic Kidney Disease and Preeclampsia by means of New and Old Biomarkers? A Prospective Study

Table 3

Molecular and biophysical biomarkers.

Biomarkers: median; min–max or %	CKD; (: 35)	PE; (: 24)	Other; (: 17)	Statistical significance
sFlt-1 (pg/mL)	1893; (585–13306)	11184; (308–28182)	5472; (222–15984)
PlGF (pg/mL)	270; (11.5–1770)	39; (10.2–330.3)	94.4; (11.5–2564)
sFlt-1/PlGF ratio	8.29; (1.04–137.40)	317.32; (28.05–2619.11)	58.96; (1.46–355.45)
Normal umbilical and uterine flow	85.7%	37.5%	52.9%
Normal uterine or umbilical flow	14.3%	29.2%	29.4%
Abnormal umbilical and uterine flow	0%	33.3%	17.6%

: CKD versus PE versus Other; : CKD versus PE; : CKD versus Other; : PE versus Other.
Note. Comparisons between groups: sFlt-1: ; ; . PlGF: ; ; . Ratio sFlt1-PlGF: ; ; ; prevalence of normal flows: ; ; .
Presence of at least one impaired uteroplacental flow for diagnosis of PE and Other diseases versus CKD: sensitivity 56.1% (95% CI: 39.7%–71.5%); specificity 85.7% (95% CI: 69.7%–95.2%); PPV 82.1% (95% CI: 63.1%–93.9%); NPV value 62.5% (95% CI: 47.4%–76.0%).
PE only versus CKD: sensitivity 62.5% (95% CI: 40.6%–81.2%); specificity 85.7% (95% CI: 69.7%–95.2%); PPV 75% (95% CI: 50.9%–91.3%); NPV: 76.9% (95% CI: 60.7%–88.9%).